The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1

AIDS Research and Human Retroviruses

Volumn 32, Issue 7, 2016, Pages 636-647

  Jacobson, Jeffrey M ^a   Bosinger, Steven E ^b   Kang, Minhee ^c   Belaunzaran Zamudio, Pablo ^d   Matining, Roy M ^c   Wilson, Cara C ^e   Flexner, Charles ^f   Clagett, Brian ^g   Plants, Jill ^h   Read, Sarah ⁱ   Purdue, Lynette ⁱ   Myers, Laurie ^j   Boone, Linda ^k   Tebas, Pablo ^l   Kumar, Princy ^m   Clifford, David ⁿ   Douek, Daniel ⁱ   Silvestri, Guido ^b   Landay, Alan L ^h   Lederman, Michael M ^g  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h RUSH MEDICAL COLLEGE   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^k SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD14 ANTIGEN; CD38 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHLOROQUINE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERFERON; INTERFERON GAMMA INDUCED PROTEIN 10; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VIRUS RNA; IMMUNOLOGIC FACTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; MEMORY T LYMPHOCYTE; MIDDLE AGED; OPPORTUNISTIC INFECTION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; YOUNG ADULT; ADOLESCENT; CELLULAR IMMUNITY; CROSSOVER PROCEDURE; DRUG EFFECTS; GENE EXPRESSION PROFILING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOLOGY;

ADOLESCENT; ADULT; AGED; CD8-POSITIVE T-LYMPHOCYTES; CHLOROQUINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION PROFILING; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PLACEBOS; YOUNG ADULT;

EID: 84976485600     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2015.0336     Document Type: Article

References (45)

1. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.
2. Malaspina A, Moir S, Kottilil S, et al.: Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol 2003;170:5965-5972.
3. Hazenberg MD, Stuart JW, Otto SA, et al.: T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: A longitudinal analysis in participants before and during highly active antiretroviral therapy (HAART). Blood 2000;95:249-255.
4. Connolly NC, Riddler SA, Rinaldo CR: Proinflammatory cytokines in HIV disease-A review and rationale for new therapeutic approaches. AIDS Rev 2005;7:168-180.
5. Valdez H, Lederman MM: Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev 1997-1998:187-228.
6. Deeks SG, Kitchen CM, Liu L, et al.: Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004;104:942-947.
7. Giorgi JV, Lyles RH, Matud JL, et al.: Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002;29:346-355.
8. Fahey JL, Taylor JM,Manna B, et al.: Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS 1998;12:1581-1590.
9. Hunt PW, Martin JN, Sinclair E, et al.: T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected participants with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003;187:1534-1543.
10. Lederman MM, Calabrese L, Funderburg NT, et al.: Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011;204:1217-1226.
11. Tenorio AR, Zheng Y, Bosch RJ, et al.: Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014;210:1248-1259.
12. Emu B, Sinclair E, Favre D, et al.: Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005; 79:14169-14178.
13. Benito JM, Lopez M, Lozano S, et al.: Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005;38:373-381.
14. Brenchley JM, Price DA, Douek DC: HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006;7:235-239.
15. Sandler NG, Douek DC: Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012;10:655-666.
16. Equils O, Schito ML, Karahashi H, et al.: Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication. J Immunol 2003;170: 5159-5164.
17. Iwasaki A, Medzhitov R: Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-995.
18. Trinchieri G, Sher A: Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007; 7:179-190.
19. Lenert PS: Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther 2006;8:203.
20. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R: Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 2003;3:722-727.
21. Hong Z, Jiang Z, Liangxi W, et al.: Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int Immunopharmacol 2004;4:223-234.
22. Rutz M, Metzger J, Gellert T, et al.: Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence-and pHdependent manner. Eur J Immunol 2004;34:2541-2550.
23. Wozniacka A, Lesiak A, Narbutt J, Kobos J, Pavel S, Sysa-Jedrzejowska A: Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in participants with systemic lupus erythematosus. Lupus 2007;16:89-94.
24. Bosinger SE, Li Q, Gordon SN, et al.: Global genomic analysis reveals rapid control of a robust innate response in SIVinfected sooty mangabeys. J Clin Invest 2009;119:3556-3572.
25. Taaffe JE, Bosinger SE, Del Prete GQ, et al.: CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIVuninfected rhesus macaques. J Med Primatol 2012;41:24-42.
26. Klatt NR, Bosinger SE, Peck M, et al.: Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals. PLoS Pathog 2014;10:e1004345.
27. Rotger M, Dalmau J, Rauch A, et al.: Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest 2011;121:2391-2400.
28. Oliveira MI, Goncalves CM, Pinto M, et al.: CD6 attenuates early and late signaling events, setting thresholds for T-cell activation. Eur J Immunol 2012;42:195-205.
29. Hunt PW, Sinclair E, Rodriguez B, et al.: Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014;210: 1228-1238.
30. Bosinger SE, Jochems SP, Folkner KA, Hayes TL, Klatt NR, Silvestri G: Transcriptional profiling of experimental CD8(+) lymphocyte depletion in rhesus macaques infected with simian immunodeficiency virus SIVmac239. J Virol 2013;87:433-443.30.
31. Sperber K, Louie M, Kraus T, et al.: Hydroxychloroquine treatment of participants with human immunodeficiency virus type 1. Clin Ther 1995;17:622-636.
32. Sperber K, Chiang G, Chen H, et al.: Comparison of hydroxychloroquine with zidovudine in asymptomatic participants infected with human immunodeficiency virus type 1. Clin Ther 1997;19:913-923.
33. Engchanil C, Kosalaraksa P, Lumbiganon P, et al.: Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children. J Med Assoc Thai 2006;89:1229-1236.
34. Paton NI, Goodall RL, Dunn DT, et al.: Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected participants not receiving antiretroviral therapy: A randomized controlled trial. JAMA 2012;308: 353-361.
35. Calabrese LH, Lederman MM, Spritzler J, et al.: Placebocontrolled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. J Acquir Immune Defic Syndr 2002;29:356-362.
36. McComsey GA, Whalen CC, Mawhorter SD, et al.: Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 2001;15:321-327.
37. Jacobson JM, Greenspan JS, Spritzler J, et al.: Thalidomide for the treatment of oral aphthous ulcers in participants with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1487-1493.
38. Fredericksen BL, Wei BL, Yao J, Luo T, Garcia JV: Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol 2002; 76:11440-11446.
39. Vijaykumar TS, Nath A, Chauhan A: Chloroquine mediated molecular tuning of astrocytes for enhanced permissiveness to HIV infection. Virology 2008;381:1-5.
40. Sperber K, Kalb TH, Stecher VJ, Banerjee R, Mayer L: Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 1993;9:91-98.
41. Savarino A, Lucia MB, Rastrelli E, et al.: Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 2004;35:223-232.
42. Murray SM, Down CM, Boulware DR, et al.: Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010;84:12082-12086.
43. Piconi S, Parisotto S, Rizzardini G, et al.: Hydroxychloroquine drastically reduces immune activation in HIVinfected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011;118:3263-3272.
44. Routy JP, Angel JB, Patel M, et al.: Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected participants receiving antiretroviral therapy. HIV Med 2015;16: 48-56.
45. Savarino A, Shytaj IL: Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. Retrovirology 2015;12:51.